VasoGenix Pharmaceuticals

VasoGenix Pharmaceuticals was a development-stage biopharmaceutical company focused on the discovery and development of cardiovascular therapeutics. The company's primary research centered on synthetic analogs of Calcitonin Gene-Related Peptide (CGRP), a naturally occurring peptide known for its potent vasodilatory and cardioprotective properties. VasoGenix aimed to develop these analogs as front-line treatments for heart failure and myocardial ischemia, leveraging CGRP's ability to increase local blood flow and protect cardiac muscle cells from oxygen deprivation. Despite receiving early-stage funding and establishing research partnerships, the company appears to have ceased active drug development operations and is currently listed as dissolved.